Servicio de splicing-minigenes
Impact of mutations on splicing. A DNA variant (indicated by an arrow in the sequence) of the donor site of BRCA2 exon 13 induces its loss (skipping) in the mature transcript. This causes an ORF change and the generation of a premature STOP codon.
Functional analysis of DNA variants from disease-responsible genes can be carried out by direct patient RNA RT-PCR (usually lymphocyte RNA) or functional assay by hybrid minigenes. For obvious reasons, direct analysis of RNA from a patient would the most reliable method of establishing with certainty whether a particular DNA substitution affects splicing but patient RNA is not always available and often difficult to obtain. Splicing reporter plasmids are useful alternative tools to study ex vivo the impact of a variant on splicing. The Splicing and Genetic susceptibility group of the IBGM (CSIC, PI Eladio A. Velasco) has developed a new splicing reporter plasmid (pSAD; https://docs.google.com/file/d/0B7Ne4lHDwcbubGpfdV9xX2NmQ3M/edit?usp=sharing) to carry out splicing functional assays by hybrid minigenes, which helps to identify variants with impact on splicing. The protocol for a splicing functional analysis of a particular DNA variant of a disease-responsible gene is as simple as follows:
- Cloning of exon(s) of interest in pSAD. It is recommended to clone flanking exons to keep the genomic context that can influence on the splicing reactions. Alternatively, gene synthesis procedures can be carried out to circumvent this laborious step.
- Generation of the DNA variant by site directed-mutagenesis;
- Transfection of the wild type and mutant minigenes into eukaryotic cells;
- RNA Isolation and RT-PCR with specific primers of the constitutive exons (V1 and V2) that do not amplify RNA transcribed by the host cell;
- Electrophoresis and sequencing of RNA isoforms: characterization of anomalous events (e.g. exon skipping, use of alternative splice sites, intron retention, etc).
Outline of the cloning procedure into the pSAD vector. The insert with exon(s) is generated by PCR with a high fidelity polymerase and primers with tails containing suitable restriction sites to keep the orientation of acceptor and donor sites with those of the constitutive exons of pSAD (V1 and V2). E. coli DH5α cells are transformed and selected with ampicillin and X-Gal/IPTG. The splicing reactions in eukaryotic cells are indicated.
Splicing functional assays of BRCA2 minigene MGBR2_ex19-27: Impact on splicing of DNA variants of the acceptor and donor sites of exons 21 and 22. A) Capillary electrophoresis of fluorescent RT-PCRs
List of constructed minigenes
Breast cancer minigenes:
1 Fraile-Bethencourt et al (2019); 2 Fraile-Bethencourt et al (2017); 3 Acedo et al (2015). The CHEK2, PALB2, ATM, RAD51C and RAD51D minigenes have been developed under the H2020 grant “Breast Cancer Risk after Diagnostic Gene Sequencing (BRIDGES)” (Project Number 634935).
4 Lara et al (2014); 5 Villate et al (2018); Gailite et al (submitted 2019)
Price List (24/05/2019)1
- Bioinformatics analysis of DNA variants 20 €
- Analysis of patient samples:
- RNA extraction from blood 30 €
- Lymphocyte RT-PCR 275 €
- Splicing functional assays with hybrid minigenes:
- Construction of 1 custom minigene2 450 € (each cloning step, max. 3)
- Functional assay of a DNA variant 350 €
1 VAT not included.
2 Any human exon can be cloned.
Dr Eladio A. Velasco Sampedro (email@example.com) must be contacted for any functional test.
Eladio A. Velasco Sampedro, Staff Scientist CSIC.REFERENCES
- Fraile-Bethencourt E, Valenzuela-Palomo A, Díez-Gómez B, Goina E, Acedo A, Buratti E, Velasco EA. Mis-splicing in breast cancer: identification of pathogenic BRCA2 variants by systematic minigene assays. J Pathol. 2019; 248: 409-420. doi: 10.1002/path.5268. [Pubmed]
- Villate O; Ibarluzea N; Fraile-Bethencourt E; Valenzuela A; Velasco EA; Grozeva D; Raymond FL; Botella MP; Tejada MI (2018). Functional analyses of a novel splice variant in the CHD7 gene, found by Next Generation Sequencing, confirm its pathogenicity in a Spanish patient and diagnose him with CHARGE syndrome. Frontiers in Genetics 2018, 9: 7. DOI: 10.3389/fgene.2018.00007
- Fraile-Bethencourt E, Díez-Gómez B, Velásquez-Zapata V, Acedo A, Sanz DJ, Velasco EA (2017). Functional classification of DNA variants by hybrid minigenes: Identification of 30 spliceogenic variants of BRCA2 exons 17 and 18. PLoS Genetics 13(3):e1006691. doi: 10.1371/journal.pgen.1006691. http://journals.plos.org/plosgenetics/article?id=10.1371/journal.pgen.1006691
- Acedo A, Hernández-Moro C, Curiel-García Á, Díez-Gómez B, Velasco EA. (2015). Functional Classification of BRCA2 DNA Variants by Splicing Assays in a Large Minigene with 9 Exons. Human Mutation 36: 210–221. [PubMed]
- Lara B, Martínez MT, Blanco I, Hernández-Moro C, Velasco EA, Ferrarotti I, Rodriguez-Frias F, Perez L, Vazquez I, Alonso J, Posada M, Martínez-Delgado B. 2014. Severe alpha-1 antitrypsin deficiency in composite heterozygotes inheriting a new splicing mutation QOMadrid. Respiratory Research 15: 125. [PubMed]
- Ruiz de Garibay G, Acedo A, García-Casado Z, Gutiérrez-Enríquez S, Tosar A, Romero A, Garre P, Llort G, Thomassen M, Díez O, Pérez-Segura P, Eduardo Díaz-Rubio E, Velasco EA, Caldés T, de la Hoya M. Capillary Electrophoresis Analysis of Conventional Splicing Assays: IARC Analytical and Clinical Classification of 31 BRCA2 Genetic Variants. Human Mutation 35: 53-57. [PubMed]
- Acedo A, Sanz DJ, Duran M, Infante M, Perez-Cabornero L, Miner C, Velasco EA. 2012. Comprehensive splicing functional analysis of DNA variants of the BRCA2 gene by hybrid minigenes. Breast Cancer Res 14:R87. [PubMed]
- Baralle D, Lucassen A, Buratti E. 2009. Missed threads. The impact of pre-mRNA splicing defects on clinical practice. EMBO Rep 10:810-816. [PubMed]
- Lopez-Bigas N, Audit B, Ouzounis C, Parra G, Guigo R. 2005. Are splicing mutations the most frequent cause of hereditary disease? FEBS Lett 579:1900-1903. [PubMed]
- Sanz DJ, Acedo A, Infante M, Duran M, Perez-Cabornero L, Esteban-Cardenosa E, Lastra E, Pagani F, Miner C, Velasco EA. 2010. A high proportion of DNA variants of BRCA1 and BRCA2 is associated with aberrant splicing in breast/ovarian cancer patients. Clin Cancer Res 16:1957-1967. [PubMed]